NZM2 Stock Chart & Stats
€55.92
-€0.28(-0.50%)
At close: 4:00 PM EDT
€55.92
-€0.28(-0.50%)
Day’s Range― - ―
52-Week Range€44.99 - €57.68
Previous CloseN/A
Volume5.00
Average Volume (3M)217.00
Market Cap
€26.27B
Enterprise Value€199.87K
Total Cash (Recent Filing)€256.50M
Total Debt (Recent Filing)€1.70B
Price to Earnings (P/E)42.7
Beta0.30
Next Earnings
Aug 20, 2026EPS Estimate
0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.13
Shares Outstanding414,555,050
10 Day Avg. Volume308
30 Day Avg. Volume217
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€64.59Price Target Upside15.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Novonesis News
NZM2 FAQ
What was Novonesis’s price range in the past 12 months?
Novonesis lowest stock price was €44.99 and its highest was €57.68 in the past 12 months.
What is Novonesis’s market cap?
Novonesis’s market cap is €26.27B.
When is Novonesis’s upcoming earnings report date?
Novonesis’s upcoming earnings report date is Aug 20, 2026 which is in 17 days.
How were Novonesis’s earnings last quarter?
Novonesis released its earnings results on May 05, 2026. The company reported €0.55 earnings per share for the quarter, missing the consensus estimate of €0.699 by -€0.149.
Is Novonesis overvalued?
According to Wall Street analysts Novonesis’s price is currently Undervalued.
Does Novonesis pay dividends?
Novonesis does not currently pay dividends.
What is Novonesis’s EPS estimate?
Novonesis’s EPS estimate is 0.53.
How many shares outstanding does Novonesis have?
Novonesis has 414,555,050 shares outstanding.
What happened to Novonesis’s price movement after its last earnings report?
Novonesis reported an EPS of €0.55 in its last earnings report, missing expectations of €0.699. Following the earnings report the stock price went up 3.896%.
Which hedge fund is a major shareholder of Novonesis?
Currently, no hedge funds are holding shares in DE:NZM2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novonesis
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends internationally, serving markets in Denmark, the rest of Europe, North America, Asia Pacific, the Middle East, Africa, and Latin America. Novozymes' diverse portfolio includes protein solutions for the food and beverage sector, alongside a comprehensive suite of cleaning and hygiene offerings for industrial, medical, and household applications, such as drain openers, septic tank treatments, ware washing, and professional laundry. In agriculture, they supply solutions for various crops like corn, cotton, soybeans, and wheat, focusing on bioyield and biocontrol, in addition to animal health and nutrition products and aquaculture systems for warm water species. The company actively supports sustainable industrial processes with contributions to bioenergy (including ethanol, biodiesel, renewable diesel, biogas, and wastewater treatment), biorefining (encompassing fiber modification, bleach boosting, deposit control, starch modification, carbon capture), and applications for textiles and leather. Their extensive range of enzyme solutions, such as lipases, proteases, oxidoreductases, and carbohydrases, are crucial for processes like corn and wheat separation, liquefaction, and saccharification. Furthermore, Novozymes addresses human health with solutions targeting brain, oral, protective, immune, and gastrointestinal well-being, while also engaging in areas like biocatalysis, cell culture, and diagnostics.
NZM2 Revenue Breakdown
28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health

NZM2 Stock 12 Month Forecast
Average Price Target
€64.59
▲(15.50% Upside)










